Rapiblyk Dosage

Recommended Dosage

Administer RAPIBLYK as a continuous intravenous infusion, titrating as needed for heart rate control. There are limited data beyond 24 hours of use.

9 mcg/kg/min landiolol is equivalent to 9.6 mcg/kg/min landiolol hydrochloride.

Transitioning from RAPIBLYK Injection Therapy to Alternative Medications

When transitioning to alternative medications consider the pharmacodynamics of the medication to which the patient is being transitioned and monitor clinical response. If switched to an oral beta-blocker, the dosage of RAPIBLYK can be reduced as follows:

• Ten minutes after administration of the oral beta-blocker, reduce the infusion rate of RAPIBLYK by 50%.
• If satisfactory control is maintained for at least one hour, discontinue RAPIBLYK.

Instructions for Preparation

• Use appropriate aseptic technique for reconstitution.
• Reconstitute each 280 mg vial of RAPIBLYK with 50 mL of 0.9% Sodium Chloride Injection, USP or 5% Dextrose Injection, USP. Gently swirl to dissolve contents.
• Inspect parenteral drug products for particulate matter and discoloration prior to administration, whenever solution and container permit. The reconstituted solution should be a clear, colorless solution.
• Use immediately. The reconstituted RAPIBLYK solution storage conditions are described in Table 2.
• Discard unused portion.

Administration

Following reconstitution, the product contains 280 mg landiolol/50 mL = 5.6 mg/mL.

The infusion rate can be calculated as:

• Infusion rate (mL/hour) = target dose (mcg/kg/min) × body weight (kg) / 93